J&J study uncovered hip implant failures 2 years before recall

Johnson & Johnson ($JNJ) was aware of the alarming failure rates of ASR hip implants a year before the company stopped making them and two years before they were recalled, newly unsealed court documents show. Report | Report (sub. req.)

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.